Home/Pipeline/PTX-252

PTX-252

Acute Myeloid Leukemia (AML)

Pre-clinicalActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Pre-clinical

Status

Active

Company

Pleco Therapeutics

About Pleco Therapeutics

Pleco Therapeutics is a private, preclinical-stage biotech developing its Plecoid™ platform, which targets the tumor microenvironment to remove toxic metals and rebalance protein expression, thereby sensitizing cancers to chemotherapy. The company's lead candidate, PTX-252, is being developed for Acute Myeloid Leukemia (AML), with a positive Pre-IND meeting outcome announced in March 2025. Operating from Amsterdam, Pleco is pre-revenue and strategically targeting high-unmet-need orphan cancers to establish initial proof-of-concept and market value for its novel approach.

View full company profile

Therapeutic Areas

Oncology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active